Gene therapies for neurogenetic disorders

Area of Science:

• Neurogenetics
• Molecular Biology
• Biotechnology

Background:

• Over 1700 genes harbor pathogenic variants linked to neurogenetic disorders.
• Monogenetic neurogenetic diseases are prime candidates for gene therapy interventions.
• Challenges include the blood-brain barrier, terminally differentiated neurons, and inefficient delivery systems.

Purpose of the Study:

• To review the current state of gene therapy development for neurogenetic disorders.
• To explore emerging delivery vehicles and therapeutic strategies.
• To highlight the role of patient foundations in accelerating research.

Main Methods:

• Review of recent advancements in gene therapy delivery platforms (e.g., viral capsids, LNPs).
• Analysis of novel therapeutic strategies (e.g., RNA therapeutics, gene editing).
• Examination of the impact of patient-led initiatives on translational research.

Main Results:

• Rapid progress in gene therapy development for neurogenetic disorders post-2016.
• Emergence of innovative delivery vehicles and therapeutic modalities.
• Significant contributions of patient foundations to trial readiness and research.

Conclusions:

• Gene therapy holds significant potential for treating neurogenetic disorders.
• Overcoming delivery challenges is key to successful therapeutic application.
• Collaborative efforts between researchers and patient groups are vital for future progress.